Abstract
1. Diabetes is a major global public health problem. The prevalence of this disease is predicted to increase sharply in the coming decades, particularly in less-developed regions of the world. 2. Most premature morbidity and mortality associated with diabetes relates to markedly increased risks of major cardiovascular diseases, such as myocardial infarction and stroke (macrovascular events), as well as microvascular complications, such as nephropathy and retinopathy. 3. Hypertension is a prevalent and important risk factor for vascular events in these patients. However, observational data demonstrate a continuous relationship between blood pressure and risk of vascular events, suggesting that even those individuals considered normotensive may benefit from blood pressure lowering. 4. Trials of blood pressure lowering among mostly hypertensive individuals with diabetes have demonstrated benefit of intervention on macrovascular and microvascular outcomes. Recent data may suggest additional effects of angiotensin- converting enzyme inhibitors independent of blood pressure lowering. 5. Issues where data are lacking with respect to blood pressure lowering in diabetes include the effects of blood pressure lowering among non-hypertensi...Continue Reading
References
Feb 20, 1987·JAMA : the Journal of the American Medical Association·R D AbbottK Yano
Dec 16, 1995·Lancet·C J Wills, S Keir
Feb 1, 1995·Diabetes Care·R Klein
Jan 26, 1994·JAMA : the Journal of the American Medical Association·G VibertiJ F Pauls
Jan 1, 1993·Cardiology·J StamlerR Stamler
Nov 11, 1993·The New England Journal of Medicine·E J LewisR D Rohde
Jan 20, 1998·Lancet·N ChaturvediJ H Fuller
Mar 5, 1998·The New England Journal of Medicine·R O EstacioR W Schrier
Apr 16, 1998·Diabetes Care
Jun 13, 1998·Annals of Internal Medicine·M RavidR Rachmani
Jun 23, 1998·Lancet·L HanssonS Westerling
Sep 4, 1998·Diabetes Care·H KingW H Herman
Sep 11, 1998·BMJ : British Medical Journal
Mar 4, 1999·The New England Journal of Medicine·J TuomilehtoR Fagard
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 9, 2000·The New England Journal of Medicine
Jul 29, 2000·Controlled Clinical Trials·M LièvreD Vasmant
Aug 11, 2000·BMJ : British Medical Journal·A I AdlerR R Holman
Dec 29, 2000·Lancet·B NealUNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Oct 13, 2001·Diabetologia·UNKNOWN ADVANCE Management Committee
Nov 25, 2003·Diabetes Care·Steen AndersenUNKNOWN Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group
Jun 1, 2006·Diabetologia·I M StrattonR R Holman
Apr 30, 2008·Diabetes Care·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial Study Group
Citations
Aug 27, 2003·Metabolism: Clinical and Experimental·Diederick E Grobbee
Dec 14, 2011·Diabetes, Obesity & Metabolism·P Hamet
May 3, 2007·Blood Pressure·Vlado PerkovicUNKNOWN ADVANCE Collaborative Group
Feb 1, 2015·The Cochrane Database of Systematic Reviews·Diana V DoRobert N Frank